Cytek Biosciences Analyst Ratings
Cytek Biosciences Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/19/2023 | — | Raymond James | Initiates Coverage On | → Market Perform | |
05/11/2023 | 44.44% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
05/10/2023 | 33.33% | Goldman Sachs | $14 → $12 | Maintains | Buy |
03/07/2023 | 66.67% | Piper Sandler | $18 → $15 | Maintains | Overweight |
03/02/2023 | 55.56% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
03/02/2023 | 55.56% | Goldman Sachs | $16 → $14 | Maintains | Buy |
08/18/2022 | 77.78% | Piper Sandler | $12 → $16 | Maintains | Overweight |
08/12/2022 | 66.67% | Morgan Stanley | $11 → $15 | Maintains | Equal-Weight |
08/11/2022 | 88.89% | Goldman Sachs | $15 → $17 | Maintains | Buy |
07/14/2022 | 66.67% | Goldman Sachs | $12 → $15 | Maintains | Buy |
05/16/2022 | 33.33% | Piper Sandler | $17 → $12 | Maintains | Overweight |
05/13/2022 | 22.22% | Morgan Stanley | $18 → $11 | Maintains | Equal-Weight |
05/12/2022 | 33.33% | Goldman Sachs | $14 → $12 | Maintains | Buy |
04/13/2022 | 55.56% | Goldman Sachs | $28 → $14 | Maintains | Buy |
02/15/2022 | 100% | Morgan Stanley | $27 → $18 | Maintains | Equal-Weight |
08/17/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
08/17/2021 | 188.89% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
08/17/2021 | 211.11% | Goldman Sachs | → $28 | Initiates Coverage On | → Buy |
08/17/2021 | 211.11% | Piper Sandler | → $28 | Initiates Coverage On | → Overweight |
日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
---|---|---|---|---|---|
07/19/2023 | — | 雷蒙德·詹姆 | 啓動覆蓋開啓 | → 市場表現 | |
05/11/2023 | 44.44% | 摩根士丹利 | 14 美元 → 13 美元 | 維護 | 重量相等 |
05/10/2023 | 33.33% | 高盛 | 14 美元 → 12 美元 | 維護 | 購買 |
03/07/2023 | 66.67% | 派珀·桑德勒 | 18 美元 → 15 美元 | 維護 | 超重 |
03/02/2023 | 55.56% | 摩根士丹利 | 15 美元 → 14 美元 | 維護 | 重量相等 |
03/02/2023 | 55.56% | 高盛 | 16 美元 → 14 美元 | 維護 | 購買 |
08/18/2022 | 77.78% | 派珀·桑德勒 | 12 美元 → 16 美元 | 維護 | 超重 |
2022 年 12 月 8 日 | 66.67% | 摩根士丹利 | 11 美元 → 15 美元 | 維護 | 重量相等 |
08/11/2022 | 88.89% | 高盛 | 15 美元 → 17 美元 | 維護 | 購買 |
07/14/2022 | 66.67% | 高盛 | 12 美元 → 15 美元 | 維護 | 購買 |
05/16/2022 | 33.33% | 派珀·桑德勒 | 17 美元 → 12 美元 | 維護 | 超重 |
05/13/2022 | 22.22% | 摩根士丹利 | 18 美元 → 11 美元 | 維護 | 重量相等 |
2022 年 12 月 5 日 | 33.33% | 高盛 | 14 美元 → 12 美元 | 維護 | 購買 |
2022 年 4 月 13 日 | 55.56% | 高盛 | 28 美元 → 14 美元 | 維護 | 購買 |
2022 年 2 月 15 日 | 100% | 摩根士丹利 | 27 美元 → 18 美元 | 維護 | 重量相等 |
2021 年 8 月 17 日 | — | Cowen & Co. | 啓動覆蓋開啓 | → 跑贏大盤 | |
2021 年 8 月 17 日 | 188.89% | 摩根士丹利 | → 26 美元 | 啓動覆蓋開啓 | → 重量相等 |
2021 年 8 月 17 日 | 211.11% | 高盛 | → 28 美元 | 啓動覆蓋開啓 | → 購買 |
2021 年 8 月 17 日 | 211.11% | 派珀·桑德勒 | → 28 美元 | 啓動覆蓋開啓 | → 超重 |
What is the target price for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的目標價格是多少?
The latest price target for Cytek Biosciences (NASDAQ: CTKB) was reported by Raymond James on July 19, 2023. The analyst firm set a price target for $0.00 expecting CTKB to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
雷蒙德·詹姆斯於2023年7月19日公佈了Cytek Biosciences(納斯達克股票代碼:CTKB)的最新目標股價。這家分析公司將目標股價定爲0.00美元,預計CTKB將在12個月內跌至-100.00%(可能下跌-100.00%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的最新分析師評級是多少?
The latest analyst rating for Cytek Biosciences (NASDAQ: CTKB) was provided by Raymond James, and Cytek Biosciences initiated their market perform rating.
Cytek Biosciences(納斯達克股票代碼:CTKB)的最新分析師評級由雷蒙德·詹姆斯提供,Cytek Biosciences啓動了市場表現評級。
When is the next analyst rating going to be posted or updated for Cytek Biosciences (CTKB)?
Cytek Biosciences(CTKB)的下一個分析師評級何時公佈或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cytek Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cytek Biosciences was filed on July 19, 2023 so you should expect the next rating to be made available sometime around July 19, 2024.
分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與Cytek Biosciences的高管和客戶交談,以及聽取財報電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。Cytek Biosciences的最後一次評級是在2023年7月19日提交的,因此你應該預計下一個評級將在2024年7月19日左右公佈。
Is the Analyst Rating Cytek Biosciences (CTKB) correct?
分析師對 Cytek Biosciences (CTKB) 的評級正確嗎?
While ratings are subjective and will change, the latest Cytek Biosciences (CTKB) rating was a initiated with a price target of $0.00 to $0.00. The current price Cytek Biosciences (CTKB) is trading at is $9.00, which is out of the analyst's predicted range.
雖然評級是主觀的,會發生變化,但最新的Cytek Biosciences(CTKB)評級是最初的,目標股價爲0.00美元至0.00美元。Cytek Biosciences(CTKB)目前的交易價格爲9.00美元,超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。